

Table 14-3.08
ADAS Cog (11) - Change from Baseline to Week 24 in Male Subjects - LOCF

	Placebo (N=33)	Xanomeline Low Dose (N=34)	Xanomeline High Dose (N=39)
Baseline			
n	33	34	39
Mean (SD)	22.8 (13.45)	23.3 (14.03)	20.8 (11.11)
Median (Range)	19.0 (5;61)	21.5 (7;57)	17.0 (3;51)
Week 24			
n	33	34	39
Mean (SD)	24.7 (13.89)	25.7 (14.72)	22.7 (12.32)
Median (Range)	20.0 (5;62)	24.0 (6;57)	21.0 (3;51)
Change from Baseline			
n	33	34	39
Mean (SD)	1.9 (6.14)	2.5 (5.61)	1.8 (3.77)
Median (Range)	1.0 (-11;16)	1.0 (-6;14)	1.0 (-7;13)
p-value(Dose Response) [1][2]			0.873
p-value(Xan - Placebo) [1][3]		0.712	0.915
Diff of LS Means (SE)		0.5 (1.30)	0.1 (1.25)
95% CI		(-2.1;3.1)	(-2.4;2.6)
p-value(Xan High - Xan Low) [1][3]			0.783
Diff of LS Means (SE)			-0.3 (1.26)
95% CI			(-2.9;2.2)

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline value as a covariate.

[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.

[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas

21:05 Monday, June 26, 2006